Lipocine (NASDAQ:LPCN) Now Covered by StockNews.com

StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Thursday. The brokerage issued a hold rating on the specialty pharmaceutical company’s stock.

Separately, Alliance Global Partners started coverage on shares of Lipocine in a report on Tuesday, September 24th. They set a “buy” rating and a $10.00 target price on the stock.

Lipocine Stock Performance

Shares of LPCN stock opened at $5.23 on Thursday. The stock has a market capitalization of $27.97 million, a price-to-earnings ratio of -6.88 and a beta of 1.23. Lipocine has a one year low of $2.82 and a one year high of $11.79. The company’s 50-day simple moving average is $5.02 and its 200-day simple moving average is $5.17.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) EPS for the quarter. As a group, research analysts forecast that Lipocine will post -0.78 EPS for the current year.

Institutional Trading of Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP bought a new position in Lipocine Inc. (NASDAQ:LPCN) during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine at the end of the most recent reporting period. 9.11% of the stock is currently owned by hedge funds and other institutional investors.

Lipocine Company Profile

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.